Harbour BioMed Leverages PPD’s Biotech to Develop Innovative Therapeutics

End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.

Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.

How biopharmas are advancing their pharmacovigilance operations.

The top five episodes of our podcast in the year 2024, highlighted.

Phase III HELIOS-B trial found that Amvuttra (vutrisiran) also preserved functional capacity and quality of life in patients with transthyretin amyloidosis with cardiomyopathy.

In the study, Calquence plus chemotherapy reduced the risk of disease progression or death by 27%.